Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Discover Oncology
Published in: Discover Oncology 1/2023

Open Access 01-12-2023 | Colorectal Cancer | Research

Construction of a novel nomogram based on competing endogenous RNAs and tumor-infiltrating immune cells for prognosis prediction in elderly patients with colorectal cancer

Authors: Zhimin Tao, Bo Li, Chunyan Kang, Wei Wang, Xianzhe Li, Yaowu Du

Published in: Discover Oncology | Issue 1/2023

Login to get access

Abstract

Competitive endogenous RNAs (ceRNAs) and tumor-infiltrating immune cells play essential roles in colorectal cancer (CRC) tumorigenesis. However, their prognostic role in elderly patients with CRC is unclear. Gene expression profiles and clinical information for elderly patients with CRC were downloaded from The Cancer Genome Atlas. Univariate, LASSO, and multivariate Cox regression analyses were utilized for screening key ceRNAs and prevent overfitting. A total of 265 elderly patients with CRC were included. We constructed a novel ceRNA network consisting of 17 lncRNAs, 35 miRNAs, and 5 mRNAs. We established three prognosis predictive nomograms based on four key ceRNAs (ceRNA nomogram), five key immune cells (immune cell nomogram), and their combination (ceRNA-immune cell nomogram). Among them, the ceRNA-immune cell nomogram had the best accuracy. Furthermore, the areas under the curve of the ceRNA-immune cell nomogram were also significantly greater than the TNM stage at 1 (0.818 vs. 0.693), 3 (0.865 vs. 0.674), and 5 (0.832 vs. 0.627) years. Co-expression analysis revealed that CBX6 was positively correlated with activated dendritic cells (R = 0.45, p < 0.01), whereas negatively correlated with activated mast cells (R =− 0.43, p < 0.01). In conclusion, our study constructed three nomograms to predict prognosis in elderly patients with CRC, among which the ceRNA-immune cell nomogram had the best prediction accuracy. We inferred that the mechanism underlying the regulation of activated dendritic cells and mast cells by CBX6 might play a crucial role in tumor development and prognosis of elderly patients with CRC.
Appendix
Available only for authorised users
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.PubMedCrossRef
2.
Edwards BK, Howe HL, Ries LAG, Thun MJ, Rosenberg HM, Yancik R, Wingo PA, Jemal A, Feigal EG. Annual report to the nation on the status of cancer,1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002;94:2766–92.PubMedCrossRef
3.
4.
Atkin W, Wooldrage K, Parkin DM, Kralj-Hans I, MacRae E, Shah U, Duffy S, Cross AJ. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial. Lancet  2017;389:1299–311.PubMedPubMedCentralCrossRef
5.
Frizis H, Papadopoulos A, Akritidis G, Frizis HR, Hatzitheoharis G. Are there any differences in colorectal cancer between young and elderly patients? Tech Coloproctol. 2004;8(Suppl 1):147–s148.CrossRef
6.
Numata K, Ono Y, Toda S, Kamioka Y, Suematsu H, Sawazaki S, Tsuchida K, Higuchi A, Saeki H, Rino Y, Masuda M, Matsukawa H. Modified Glasgow Prognostic score and Carcinoembryonic Antigen Predict Poor Prognosis in Elderly Patients with Colorectal Cancer. Oncol Res Treat. 2020;43:125–33.PubMedCrossRef
7.
8.
9.
Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, Chen N, Sun F, Fan Q. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010;38:5366–83.PubMedPubMedCentralCrossRef
10.
Wang S-H, Ma F, Tang Z-H, Wu X-C, Cai Q, Zhang M-D, Weng M-Z, Zhou D, Wang J-D, Quan Z-W. Long non-coding RNA H19 regulates FOXM1 expression by competitively binding endogenous mir-342-3p in gallbladder cancer. J Exp Clin Cancer Res: CR. 2016;35:160.PubMedPubMedCentralCrossRef
11.
Wang W, Lou W, Ding B, Yang B, Lu H, Kong Q, Fan W. A novel mRNA-miRNA-lncRNA competing endogenous RNA triple sub-network associated with prognosis of pancreatic cancer. Aging. 2019;11:2610–27.PubMedPubMedCentralCrossRef
12.
Cheng Y, Liu C, Liu Y, Su Y, Wang S, Jin L, Wan Q, Liu Y, Li C, Sang X, Yang L, Liu C, Wang X, Wang Z. Immune Microenvironment related competitive endogenous RNA network as powerful predictors for Melanoma Prognosis based on WGCNA Analysis. Front Oncol. 2020;10:577072.PubMedPubMedCentralCrossRef
13.
Yuan Y, Jiang Y-C, Sun C-K, Chen Q-M. Role of the tumor microenvironment in tumor progression and the clinical applications (review). Oncol Rep. 2016;35:2499–515.PubMedCrossRef
14.
Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, Validire P, Ingels A, Cathelineau X, Fridman WH, Sautès-Fridman C. The clinical role of the TME in solid cancer. Br J Cancer. 2019;120:45–53.PubMedCrossRef
15.
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc P-H, Trajanoski Z, Fridman W-H. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.PubMedCrossRef
16.
Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Chang A, Mulé J. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet  2000;356:1163–5.PubMedCrossRef
17.
Huang R, Meng T, Chen R, Yan P, Zhang J, Hu P, Zhu X, Yin H, Song D, Huang Z. The construction and analysis of tumor-infiltrating immune cell and ceRNA networks in recurrent soft tissue sarcoma. Aging. 2019;11:10116–43.PubMedPubMedCentralCrossRef
18.
Huang R, Wu J, Zheng Z, Wang G, Song D, Yan P, Yin H, Hu P, Zhu X, Wang H, Lv Q, Meng T, Huang Z, Zhang J. The construction and analysis of ceRNA Network and patterns of Immune Infiltration in Mesothelioma with Bone Metastasis. Front Bioeng Biotechnol. 2019;7:257.PubMedPubMedCentralCrossRef
19.
Li J-H, Liu S, Zhou H, Qu L-H, Yang J-H. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:D92–7.PubMedCrossRef
20.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504.PubMedPubMedCentralCrossRef
21.
Li X, Xie M, Yin S, Xiong Z, Mao C, Zhang F, Chen H, Jin L, Lan P, Lian L. Identification and validation of a six Immune-Related genes signature for Predicting prognosis in patients with stage II colorectal Cancer. Front Genet. 2021;12:666003.PubMedPubMedCentralCrossRef
22.
Zhang M, Wang X, Chen X, Zhang Q, Hong J. Novel Immune-Related gene signature for risk stratification and prognosis of Survival in Lower-Grade Glioma. Front Genet. 2020;11:363.PubMedPubMedCentralCrossRef
23.
Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Ã, Kampf C, Sjöstedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA-K, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist P-H, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J. Tissue-based map of the human proteome. Science. 2015;347:1260419.PubMedCrossRef
24.
Liposits G, Eshøj HR, Möller S, Winther SB, Skuladottir H, Ryg J, Hofsli E, Shah C-H, Poulsen L, Berglund Ã, Qvortrup C, Österlund P, Glimelius B, Sorbye H, Pfeiffer P. Quality of life in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy-the randomized NORDIC9-study. Cancers. 2021;13:2604.PubMedPubMedCentralCrossRef
25.
Douaiher J, Ravipati A, Grams B, Chowdhury S, Alatise O, Are C. Colorectal cancer-global burden, trends, and geographical variations. J Surg Oncol. 2017;115:619–30.PubMedCrossRef
26.
Olsson L, Hammarström M-L, Israelsson A, Lindmark G, Hammarström S. Allocating colorectal cancer patients to different risk categories by using a five-biomarker mRNA combination in lymph node analysis. PLoS ONE. 2020;15:e0229007.PubMedPubMedCentralCrossRef
27.
Liu S, Cao Q, An G, Yan B, Lei L. Identification of the 3-lncRNA signature as a prognostic biomarker for colorectal cancer. Int J Mol Sci. 2020;21:9359.PubMedPubMedCentralCrossRef
28.
Jiang J, Bi Y, Liu X-P, Yu D, Yan X, Yao J, Liu T, Li S. To construct a ceRNA regulatory network as prognostic biomarkers for bladder cancer. J Cell Mol Med. 2020;24:5375–86.PubMedPubMedCentralCrossRef
29.
Cheng R, Wang B, Cai X-R, Chen Z-S, Du Q, Zhou L-Y, Ye J-M, Chen Y-L. CD276 promotes vasculogenic mimicry formation in Hepatocellular Carcinoma via the PI3K/AKT/MMPs pathway. Onco Targets Ther. 2020;13:11485–98.PubMedPubMedCentralCrossRef
30.
Zhang C, Hao X. Prognostic significance of CD276 in non-small cell lung cancer. Open Med (Wars). 2019;14:805–12.PubMedCrossRef
31.
Liang J, Liu Z, Pei T, Xiao Y, Zhou L, Tang Y, Zhou C, Wu K, Zhang F, Zhang F, Yin X, Chen N, Wei X, Lu Y, Zhu Y. Clinicopathological and prognostic characteristics of CD276 (B7-H3) expression in adrenocortical carcinoma. Dis Markers. 2020;2020:5354825.PubMedPubMedCentralCrossRef
32.
Takashima Y, Kawaguchi A, Hayano A, Yamanaka R. CD276 and the gene signature composed of GATA3 and LGALS3 enable prognosis prediction of glioblastoma multiforme. PLoS ONE. 2019;14:e0216825.PubMedPubMedCentralCrossRef
33.
Zheng H, Jiang W-H, Tian T, Tan H-S, Chen Y, Qiao G-L, Han J, Huang S-Y, Yang Y, Li S, Wang Z-G, Gao R, Ren H, Xing H, Ni J-S, Wang L-H, Ma L-J. Zhou W-P: CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma. Oncotarget. 2017;8:18872–84.PubMedPubMedCentralCrossRef
34.
Bernstein E, Duncan EM, Masui O, Gil J, Heard E, Allis CD. Mouse polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. Mol Cell Biol. 2006;26:2560–9.PubMedPubMedCentralCrossRef
35.
Kaustov L, Ouyang H, Amaya M, Lemak A, Nady N, Duan S, Wasney GA, Li Z, Vedadi M, Schapira M, Min J, Arrowsmith CH. Recognition and specificity determinants of the human cbx chromodomains. J Biol Chem. 2011;286:521–9.PubMedCrossRef
36.
37.
Liu X, Ma L, Rao Q, Mao Y, Xin Y, Xu H, Li C, Wang X. MiR-1271 inhibits ovarian cancer growth by targeting cyclin G1. Med Sci Monitor: Int Med J Expl Clin Res. 2015;21:3152–8.CrossRef
38.
Zhang B, Chen J, Cui M, Jiang Y. LncRNA ZFAS1/miR-1271-5p/HK2 promotes Glioma Development through regulating proliferation, Migration, Invasion and apoptosis. Neurochem Res. 2020;45:2828–39.PubMedCrossRef
39.
Ge P, Wang W, Li L, Zhang G, Gao Z, Tang Z, Dang X, Wu Y. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of colorectal cancer. Biomed Pharmacother = Biomed Pharmacother. 2019;118:109228.PubMedCrossRef
40.
Meng J, Liu Y, Guan S, Fan S, Zhou J, Zhang M, Liang C. The establishment of immune infiltration based novel recurrence predicting nomogram in prostate cancer. Cancer Med. 2019;8:5202–13.PubMedPubMedCentralCrossRef
41.
Novy P, Quigley M, Huang X, Yang Y. CD4 T cells are required for CD8 T cell survival during both primary and memory recall responses. J Immunol. 2007;179:8243–51.PubMedCrossRef
42.
Zhang S-C, Hu Z-Q, Long J-H, Zhu G-M, Wang Y, Jia Y, Zhou J, Ouyang Y, Zeng Z. Clinical implications of Tumor-Infiltrating Immune cells in breast Cancer. J Cancer. 2019;10:6175–84.PubMedPubMedCentralCrossRef
43.
Wang J, Li Z, Gao A, Wen Q, Sun Y. The prognostic landscape of tumor-infiltrating immune cells in cervical cancer. Biomed Pharmacother = Biomed Pharmacother. 2019;120:109444.PubMedCrossRef
44.
Li J, Li X, Zhang C, Zhang C, Wang H. A signature of tumor immune microenvironment genes associated with the prognosis of non–small cell lung cancer. Oncol Rep. 2020;43:795–806.PubMed
45.
Katsuta E, Qi Q, Peng X, Hochwald SN, Yan L, Takabe K. Pancreatic adenocarcinomas with mature blood vessels have better overall survival. Sci Rep. 2019;9:1310.PubMedPubMedCentralCrossRef
46.
Li Q, Pan Y, Cao Z, Zhao S. Comprehensive Analysis of Prognostic Value and Immune Infiltration of Chromobox Family Members in Colorectal Cancer. Front Oncol. 2020;10:582667.PubMedPubMedCentralCrossRef
47.
Zhu Y, Pu Z, Li Z, Lin Y, Li N, Peng F. Comprehensive Analysis of the expression and prognosis value of Chromobox Family Members in Clear Cell Renal Cell Carcinoma. Front Oncol. 2021;11:700528.PubMedPubMedCentralCrossRef
48.
Hempel Sullivan H, Maynard JP, Heaphy CM, Lu J, De Marzo AM, Lotan TL, Joshu CE, Sfanos KS. Differential mast cell phenotypes in benign versus cancer tissues and prostate cancer oncologic outcomes. J Pathol. 2021;253:415–26.PubMedCrossRef
49.
Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB, Huntsman DG. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat. 2008;107:249–57.PubMedCrossRef
50.
Hempel HA, Cuka NS, Kulac I, Barber JR, Cornish TC, Platz EA, De Marzo AM, Sfanos KS. Low Intratumoral mast cells are Associated with a higher risk of prostate Cancer recurrence. Prostate. 2017;77:412–24.PubMedCrossRef
Metadata
Title
Construction of a novel nomogram based on competing endogenous RNAs and tumor-infiltrating immune cells for prognosis prediction in elderly patients with colorectal cancer
Authors
Zhimin Tao
Bo Li
Chunyan Kang
Wei Wang
Xianzhe Li
Yaowu Du
Publication date
01-12-2023
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-023-00742-y

Other articles of this Issue 1/2023

Discover Oncology 1/2023 Go to the issue

Research

Senescence-associated secretory phenotype constructed detrimental and beneficial subtypes and prognostic index for prostate cancer patients undergoing radical prostatectomy

Review

Awareness of intratumoral bacteria and their potential application in cancer treatment

Research

Machine learning to predict overall short-term mortality in cutaneous melanoma

Research

Pan-cancer analyses of senescence-related genes in extracellular matrix characterization in cancer

Clinical Trial

OncoVee™-MiniPDX-guided anticancer treatment for HER2-negative intermediate-advanced gastric cancer patients: a single-arm, open-label phase I clinical study

Review

Modern treatment strategies in pediatric oncology and hematology
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits